GPCR רווח נקי למניה ב-12 החודשים האחרונים structuretx.com
Structure Therapeutics relies on transparent management and a strong R&D base within the GLP-1 segment. The rolling annual earnings per share snapshot on GURU.Markets contains data where the value of -3.06 serves as the current metric, confirming the company's status as an ambitious innovator in the fight against obesity. High patent barriers and strict FDA requirements protect the company's technological advantage, shutting out smaller players.
%20%D7%A8%D7%95%D7%95%D7%97%20%D7%9C%D7%9E%D7%A0%D7%99%D7%94%20%D7%91%D7%90%D7%A8%D7%91%D7%A2%D7%AA%20%D7%94%D7%A8%D7%91%D7%A2%D7%95%D7%A0%D7%99%D7%9D%20%D7%94%D7%90%D7%97%D7%A8%D7%95%D7%A0%D7%99%D7%9D&width=1200&height=400&colorIndex=0&v=mwa76aez.ocr-7cpmfb4&start=20220704&end=20261110&filename=GURU_Markets_-_GPCR_-_Structure-Therapeutics_-_Earnings-per-share-for-the-last-four-quarters "Structure Pharma - רווח נקי למניה (EPS TTM) GPCR (תקופה 28.04.2023 - 10.11.2026) | 👁️GURU.Markets👁️")
פילוחים אנליטיים ודוחות נתונים של חברת Structure Therapeutics Inc (GPCR)
This indicator calculates the aggregate net income over four quarters distributed per common share, allowing for an assessment of real profit generation efficiency regardless of the issuance volume. The negative trend in the 12-month net income per share chart is expected for Structure Therapeutics (GPCR), as colossal development costs for oral GLP-1 agonists temporarily outweigh current revenues.
